Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

HRA

Patient speaking to doctor

The outcomes are already chosen. So when can patients really shape them?

Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.

Cuttsy + Cuttsy

- PMLiVE

MHRA approves Pharma Mar’s lurbinectedin for extensive-stage small cell lung cancer

The treatment is for adults in combination with atezolizumab

- PMLiVE

Moderna’s updated COVID-19 mRNA vaccine approved by MHRA

The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme

- PMLiVE

Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes

The UK is the first country in Europe to authorise the oral medication

Woman with headache

It’s time to stop calling adverse events ‘manageable’

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.

Cuttsy + Cuttsy

Man reading pamphlet

Where translation falls short in practice

Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.

Cuttsy + Cuttsy

- PMLiVE

J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis

Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes

- PMLiVE

MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment

SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK

Scientist

UK clinical trial regs are changing — here’s what’s happening

Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.

Cuttsy + Cuttsy

- PMLiVE

Atrogi moves forward in phase 1 trial for oral candidate to improve metabolic and muscle health

First-in-class oral therapy mimics the effects of exercise with broad potential as a novel treatment for muscle-sparing weight loss

- PMLiVE

MHRA approves Leqselvi for severe alopecia areata

Around 30% of patients saw 80% more scalp hair after 24 weeks of treatment

- PMLiVE

LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus

There are currently no approved treatments specifically indicated for LS in the US or Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links